API | terizidone

terizidone Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Terizidone is a drug used in the treatment of tuberculosis. Terizidone is mainly used in multi-drug-resistant tuberculosis (MDR-TB) in conjunction with other second-line drugs. It is a derivate of cycloserine and it is bacteriostatic. ^Wikipedia

Chemistry

SMILES: O=C1NOCC1\N=C\c2ccc(\C=N\C3CONC3=O)cc2
InChIKey: ODKYYBOHSVLGNU-IAGONARPSA-N
Mol. Mass: 302.29
ALogP: -0.62 Partition coefficient
ChEMBL Molecule:
terizidone

More Chemistry

Pharmacology

Mechanisms of Action:
- Alanine racemase, biosynthetic (Escherichia coli K-12) ^UniProt
- D-alanine--D-alanine ligase (Mycobacterium tuberculosis H37Rv) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Infections

Experimental Indications - Clinical Trial Phases 1-4 (5)

Bacterial Infections ()

Extensively Drug-Resistant Tuberculosis (Phase 2/Phase 3)

HIV Infections (Phase 4)

Tuberculosis (Phase 2/Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 2/Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue